Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 44M | 6M | 0 | 0 | 0 |
| Gross Profit | 42M | 6M | 0 | 0 | -1M |
| Operating Income | -42M | -61M | -79M | -89M | -75M |
| EBITDA | -40M | -58M | -77M | -87M | -74M |
| Net Income | -35M | -58M | -76M | -88M | -76M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$8.79
+0.46% today
1Y Change
-11.41%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xilio Therapeutics, Inc. (XLO) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $8.79 and down 11.4% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +589.9%, EPS growth of +72.5%, a dividend yield of 0.0%. What stands out right now is revenue +589.9%, EPS +72.5%, free cash flow +70.1% with operating margin -95.9% and ROIC -42.1%. Valuation is more restrained than many high-expectation growth names at price/sales 1.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines XLO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XLO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XLO Max Drawdown
-40.90%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XLO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$75.8M
+14.1% YoY
Free Cash Flow
-$81.9M
-5.5% YoY
Revenue Growth
+589.9%
EPS Growth
+72.5%
Gross Margin
96.5%
Net Margin
-80.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 44M | 6M | 0 | 0 | 0 |
| Gross Profit | 42M | 6M | 0 | 0 | -1M |
| Operating Income | -42M | -61M | -79M | -89M | -75M |
| EBITDA | -40M | -58M | -77M | -87M | -74M |
| Net Income | -35M | -58M | -76M | -88M | -76M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 138M | 55M | 45M | 120M | 198M |
| Total Assets | 155M | 71M | 61M | 139M | 222M |
| Total Liabilities | 119M | 53M | 24M | 34M | 36M |
| Shareholder Equity | 35M | 18M | 37M | 106M | 185M |
| Total Debt | 7M | 8M | 11M | 20M | 21M |
| Net Debt | -131M | -47M | -33M | -100M | -177M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
81M
-6.6% YoY
Capital Expenditures
1M
+41.1% YoY
Free Cash Flow
82M
-5.5% YoY
Key ratios
Gross Margin
96.5%
Operating Margin
-95.9%
Net Margin
-80.1%
ROE
-311.8%
Debt / Equity
0.20x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.